Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 22

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 22
---
 |       208,027 |
| 1-for-125                                       |     |       166,421 |
| 1-for-150                                       |     |       138,685 |

____________ (1)Excludes the effect of fractional share treatment. We are exploring various sources of financing, including through potential future sales of Common Stock or other securities. There can be no assurance, however, even if the Reverse Stock Split is approved and implemented, that any financing transaction would be undertaken or completed. If we are unable to successfully raise sufficient additional capital, through future sales of Common Stock or other securities or through strategic and collaborative arrangements, we will not have sufficient cash to fund our planned business operations and or may not be able to continue as a going concern. As of the Record Date, we had 20,802,671 shares of Common Stock issued and outstanding, 74,151 shares of Common Stock reserved for issuance upon the exercise of outstanding options, 159,724shares of Common Stock reserved for issuance upon the exercise of outstanding Warrants (as defined below), and 49,344 shares of Common Stock reserved for future issuances under the 2024 Plan. As of the Record Date, we had 1,429shares of Series A convertible preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”), 7shares of Series C convertible preferred stock, par value $0.0001 per share (the “Series C Preferred Stock”) issued and outstanding, 5,368shares of Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”) issued and outstanding and 3,816 shares of Series E convertible preferred stock, par value $0.0001 per share (the “Series E Preferred Stock”) issued and outstanding. Based upon a conversion price of $0.05, the shares of Series A Preferred Stock are convertible into 28,580,000 shares of Common Stock, the shares of Series C Preferred Stock are convertible into 140,000shares of Common Stock, and the shares of Series D Preferred Stock are convertible into 107,360,000shares of Common Stock and based upon a conversion price of $4.1625, the shares of Series E Preferred Stock are convertible into 916,757shares of Common Stock. If the Alternate Conversion Price is applied to determining the number of shares issuable upon conversion of the outstanding shares of Series A Preferred Stock, Series C Preferred Stock and/or Series D Preferred Stock